32 related articles for article (PubMed ID: 38701792)
1. Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas.
Scheich S; Chen J; Liu J; Schnütgen F; Enssle JC; Ceribelli M; Thomas CJ; Choi J; Morris V; Hsiao T; Nguyen H; Wang B; Bolomsky A; Phelan JD; Corcoran S; Urlaub H; Young RM; Häupl B; Wright GW; Huang DW; Ji Y; Yu X; Xu W; Yang Y; Zhao H; Muppidi J; Pan KT; Oellerich T; Staudt LM
Cancer Discov; 2023 Aug; 13(8):1862-1883. PubMed ID: 37141112
[TBL] [Abstract][Full Text] [Related]
2. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
3. USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.
Wu Y; Gu H; Bao Y; Lin T; Wang Z; Gu D; Shen H; Xian H; Fan Y; Mao R
Cell Biochem Funct; 2022 Jun; 40(4):379-390. PubMed ID: 35411950
[TBL] [Abstract][Full Text] [Related]
4. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.
Bogusz AM; Baxter RH; Currie T; Sinha P; Sohani AR; Kutok JL; Rodig SJ
Clin Cancer Res; 2012 Nov; 18(22):6122-35. PubMed ID: 22966017
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.
Choi J; Ceribelli M; Phelan JD; Häupl B; Huang DW; Wright GW; Hsiao T; Morris V; Ciccarese F; Wang B; Corcoran S; Scheich S; Yu X; Xu W; Yang Y; Zhao H; Zhou J; Zhang G; Muppidi J; Inghirami GG; Oellerich T; Wilson WH; Thomas CJ; Staudt LM
Cancer Cell; 2024 May; 42(5):833-849.e12. PubMed ID: 38701792
[TBL] [Abstract][Full Text] [Related]
6. Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.
Profitós-Pelejà N; Santos JC; Marín-Niebla A; Roué G; Ribeiro ML
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205606
[TBL] [Abstract][Full Text] [Related]
7. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
8. B-cell receptor signaling as a driver of lymphoma development and evolution.
Niemann CU; Wiestner A
Semin Cancer Biol; 2013 Dec; 23(6):410-21. PubMed ID: 24060900
[TBL] [Abstract][Full Text] [Related]
9. B-cell receptor signaling in diffuse large B-cell lymphoma.
Young RM; Shaffer AL; Phelan JD; Staudt LM
Semin Hematol; 2015 Apr; 52(2):77-85. PubMed ID: 25805587
[TBL] [Abstract][Full Text] [Related]
10. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.
Dunleavy K; Erdmann T; Lenz G
Cancer Treat Rev; 2018 Apr; 65():41-46. PubMed ID: 29549872
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]